Participation in a Research Registry for Immune Disorders

Wiskott-Aldrich Syndrome Clinical Trial

Official title:

NIH Participation to USIDNET Registry

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01953016
• Other study ID #: 130199
• Secondary ID: 13-HG-0199
• Status: Completed
• Start date: September 30, 2013
• Est. completion date: July 19, 2023

Study information

• Verified date: July 2023
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background:

• People with primary immune deficiency diseases (PIDD) have weak immune systems. This makes it hard for their bodies to fight infection. The Immune Deficiency Foundation has a network to collect data about people with PIDD. It is called the United States Immunodeficiency Network. It will help doctors and scientists better understand these disorders. The goal is to get medical data for everyone with these disorders in the U.S. and Canada. Data will be stored in a registry. Researchers can use it to study if these disorders are increasing. They can also learn how the disorders are diagnosed and treated.

Objectives:

• To collect data on people with primary immune deficiency disorders.

Eligibility:

• People who have a PIDD.

Design:

• Data can be added with no record of personal identity.

• Data can be added with identity kept separate. This data will be linked to the registry by a code number.

• Data for the registry includes:

• Family history

• Disease treatment

• Disease characteristics

• Medical history

• Laboratory data

Description:

The purpose of this protocol is to provide a resource for clinical and laboratory research through enrollment of known immunodeficiency patients into a national registry, the US Immunodeficiency Network (USIDNET). The registry data will expand NIH s and the nation s knowledge base about immune deficiency disorders and genetic mutations that lead to these disorders. Additional registrants from NIH protocols will not only increase the understanding of the molecular basis of these disorders, but also will serve to document and track the incidence and progression of complications.

Objectives and specific aims

The purpose of this proposal is to create a mechanism for depositing NIH data into USIDNET. The patient Registry is designed to obtain longitudinal data on a large number of patients with primary immunodeficiency diseases, and genetic carriers of these defects in order to:

• Learn more about the phenotypic variations seen in a large number of individual patients with the same rare molecular diagnosis.

• Determine the natural history of these genetic disorders of immunity and establish genotype-phenotype correlations.

• Learn effects of various treatment protocols used in these patients over time, including unexpected side effects that may be unique to a particular diagnostic group.

• To evaluate quality of life using standard tools and correlate these with genotype and treatment history.

• To promote collaborative research amongst interested investigators by identifying a larger pool of potential research subjects than would be available at their own institutions

• To identify patients with a specific diagnosis for potential participation in multi-institutional clinical trials designed for diagnosis or therapy or their specific disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 716
• Est. completion date: July 19, 2023
• Est. primary completion date: May 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Month and older

Eligibility

• INCLUSION CRITERIA

Individuals of all ages, gender, and races with an immunodeficiency disorder from NIH studies will be accepted for registration. No healthy volunteers will be enrolled.

EXCLUSION CRITERIA

Individuals with immunodeficiency associated with HIV infection, chemotherapy or other immunosuppressive therapies will not be accepted for registration unless there is clear evidence that these individuals also have a genetically determined immunodeficiency disease as well. Adult individuals who do not give informed consent will also be excluded.

Related Conditions & MeSH terms

• APECED
• CGD
• Immunologic Deficiency Syndromes
• Primary Immunodeficiencies
• Primary Immunodeficiency Diseases
• SCID
• Wiskott-Aldrich Syndrome

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland

Sponsors (3)

Lead Sponsor	Collaborator
National Human Genome Research Institute (NHGRI)	National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence	The Registry will provide a minimum estimate of the prevalence of each disorder in the US, a comprehensive clinical picture of each disorder, and a resource for clinical and laboratory research.	Ongoing

External Links

•   NIH Clinical Center Detailed Web Page